Race and income converge to shape women's experiences with advanced breast cancer

ATLANTA To determine the challenges of coping with metastatic breast cancer, researchers at the University of Pittsburgh schools of Nursing and Medicine evaluated the impact of race and income on women's experiences with the disease. They found that low-income African-American women were more likely to report physical and social distress and uncertainty about their future than other groups evaluated in the study. The results of the study were announced today at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting in Atlanta.

"As more and more women are living with metastatic breast cancer, it becomes ever more important to look at how women experience the disease differently based on their unique circumstances," said Margaret Quinn Rosenzweig, Ph.D., assistant professor, department of acute and tertiary care, University of Pittsburgh School of Nursing. "While we know that equitable treatment and symptom management are critical to breast cancer survival, we know much less about how quality of life and symptom distress vary according to women's race and income level, particularly for women living with advanced breast cancer."

The study looked at how women perceived barriers to treatment and to symptom management by evaluating the experiences of 57 women with metastatic breast cancer. Based on self-reporting, women were categorized into four groups: eight low-income African-American women, eight high-income African-American women, 16 low-income white women, and 25 high-income white women. Women filled out questionnaires on socio-demographics, symptom distress and quality of life, and were interviewed by the researchers to assess their experience with symptoms, self-care strategies and barriers to managing their symptoms.

The researchers found much higher levels of symptom distress and lower levels of quality of life reported by low-income African-American women than women from the other racial and economic groups. During the in'"/>

(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...

(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...

(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...

(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...

(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...

(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...

(Date:12/8/2016)... Dec. 8, 2016 Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...